marlborough pharmaceuticals limited Company Information
Company Number
05339752
Next Accounts
14 days late
Industry
Other business support service activities n.e.c.
Shareholders
atnahs pharma uk limited
Group Structure
View All
Contact
Registered Address
sovereign house miles gray road, basildon, essex, SS14 3FR
Website
www.marlborough-pharma.co.ukmarlborough pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of MARLBOROUGH PHARMACEUTICALS LIMITED at £36.1k based on a Turnover of £4k and 9.02x industry multiple (adjusted for size and gross margin).
marlborough pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of MARLBOROUGH PHARMACEUTICALS LIMITED at £0 based on an EBITDA of £-306k and a 66.51x industry multiple (adjusted for size and gross margin).
marlborough pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of MARLBOROUGH PHARMACEUTICALS LIMITED at £59.9m based on Net Assets of £25.5m and 2.35x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Marlborough Pharmaceuticals Limited Overview
Marlborough Pharmaceuticals Limited is a live company located in essex, SS14 3FR with a Companies House number of 05339752. It operates in the other business support service activities n.e.c. sector, SIC Code 82990. Founded in January 2005, it's largest shareholder is atnahs pharma uk limited with a 100% stake. Marlborough Pharmaceuticals Limited is a mature, micro sized company, Pomanda has estimated its turnover at £4k with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
Marlborough Pharmaceuticals Limited Health Check
Pomanda's financial health check has awarded Marlborough Pharmaceuticals Limited a 1.5 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 7 areas for improvement. Company Health Check FAQs
2 Strong
0 Regular
7 Weak
Size
annual sales of £4k, make it smaller than the average company (£3.1m)
£4k - Marlborough Pharmaceuticals Limited
£3.1m - Industry AVG
Growth
3 year (CAGR) sales growth of -94%, show it is growing at a slower rate (4.1%)
-94% - Marlborough Pharmaceuticals Limited
4.1% - Industry AVG
Production
with a gross margin of 1275%, this company has a lower cost of product (38.5%)
1275% - Marlborough Pharmaceuticals Limited
38.5% - Industry AVG
Profitability
an operating margin of -11175% make it less profitable than the average company (6.5%)
-11175% - Marlborough Pharmaceuticals Limited
6.5% - Industry AVG
Employees
with 1 employees, this is below the industry average (20)
- Marlborough Pharmaceuticals Limited
20 - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- Marlborough Pharmaceuticals Limited
- - Industry AVG
Efficiency
resulting in sales per employee of £4k, this is less efficient (£141.2k)
- Marlborough Pharmaceuticals Limited
£141.2k - Industry AVG
Debtor Days
it gets paid by customers after 730 days, this is later than average (40 days)
730 days - Marlborough Pharmaceuticals Limited
40 days - Industry AVG
Creditor Days
its suppliers are paid after -77 days, this is quicker than average (34 days)
-77 days - Marlborough Pharmaceuticals Limited
34 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Marlborough Pharmaceuticals Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Marlborough Pharmaceuticals Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 1.6%, this is a lower level of debt than the average (60.6%)
1.6% - Marlborough Pharmaceuticals Limited
60.6% - Industry AVG
MARLBOROUGH PHARMACEUTICALS LIMITED financials
Marlborough Pharmaceuticals Limited's latest turnover from March 2023 is £4 thousand and the company has net assets of £25.5 million. According to their latest financial statements, we estimate that Marlborough Pharmaceuticals Limited has 1 employee and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Jan 2011 | Jan 2010 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Turnover | 4,000 | 5,375,000 | 10,844,000 | 15,424,371 | 16,113,636 | 17,072,523 | 18,053,826 | 15,814,489 | 7,443,860 | 3,395,368 | ||||
Other Income Or Grants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
Cost Of Sales | -47,000 | 1,041,000 | 551,000 | 1,218,932 | 1,241,131 | 1,170,617 | 1,405,307 | 1,619,908 | 1,587,850 | 2,112,609 | ||||
Gross Profit | 51,000 | 4,334,000 | 10,293,000 | 14,205,439 | 14,872,505 | 15,901,906 | 16,648,519 | 14,194,581 | 5,856,010 | 1,282,759 | ||||
Admin Expenses | 498,000 | 1,956,000 | 4,965,000 | 6,485,981 | 6,798,687 | 7,303,584 | 7,321,731 | 6,260,096 | 1,323,520 | 888,348 | ||||
Operating Profit | -447,000 | 2,378,000 | 5,328,000 | 7,719,458 | 8,073,818 | 8,598,322 | 9,326,788 | 7,934,485 | 4,532,490 | 394,411 | ||||
Interest Payable | 0 | 0 | 0 | 0 | 0 | 143 | 0 | 0 | 0 | 0 | ||||
Interest Receivable | 451,000 | 0 | 37,000 | 56 | 769 | 6 | 10,196 | 24,518 | 28,455 | 0 | ||||
Pre-Tax Profit | 4,000 | 2,378,000 | 5,365,000 | 7,767,902 | 8,103,452 | 8,596,896 | 9,336,426 | 7,957,159 | 4,560,945 | 395,058 | ||||
Tax | -22,000 | -84,000 | -204,000 | -1,150 | -1,523,167 | -1,539,554 | -1,829,473 | -1,708,027 | -384,450 | 0 | ||||
Profit After Tax | -18,000 | 2,294,000 | 5,161,000 | 7,766,752 | 6,580,285 | 7,057,342 | 7,506,953 | 6,249,132 | 4,176,495 | 395,058 | ||||
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 5,500,000 | 15,370,550 | 1,003,868 | 0 | 0 | ||||
Retained Profit | -18,000 | 2,294,000 | 5,161,000 | 7,766,752 | 6,580,285 | 1,557,342 | -7,863,597 | 5,245,264 | 4,176,495 | 395,058 | ||||
Employee Costs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Number Of Employees | ||||||||||||||
EBITDA* | -306,000 | 2,687,000 | 7,098,000 | 7,736,458 | 8,073,818 | 8,598,322 | 9,643,148 | 8,286,179 | 4,891,120 | 615,841 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Jan 2011 | Jan 2010 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tangible Assets | 187,000 | 205,000 | 411,000 | 161,812 | 46,078 | 46,078 | 44,098 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 3,303,000 | 3,352,000 | 3,216,000 | 1,709,874 | 1,024,623 | 749,489 | 222,965 | 316,360 | 668,054 | 867,426 | 1,046,914 | 1,298,457 | 1,550,000 | 1,550,000 |
Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 480,000 | 480,000 | 480,000 | 0 | 0 |
Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 33,704 |
Total Fixed Assets | 3,490,000 | 3,557,000 | 3,627,000 | 1,871,686 | 1,070,701 | 795,567 | 267,063 | 316,360 | 668,054 | 1,347,426 | 1,526,914 | 1,778,457 | 1,550,000 | 1,583,704 |
Stock & work in progress | 0 | 128,000 | 808,000 | 431,028 | 381,485 | 315,516 | 417,532 | 537,705 | 662,429 | 317,953 | 711,404 | 400,043 | 288,270 | 249,936 |
Trade Debtors | 8,000 | 76,000 | 1,800,000 | 3,001,040 | 0 | 3,358,233 | 1,671,327 | 1,841,171 | 1,784,862 | 506,576 | 965,951 | 494,407 | 352,615 | 277,870 |
Group Debtors | 22,356,000 | 22,337,000 | 17,977,000 | 17,661,985 | 17,912,220 | 6,113,914 | 2,095,440 | 6,330,284 | 0 | 0 | 0 | 0 | 0 | 0 |
Misc Debtors | 55,000 | 11,000 | 2,000 | 13,337 | 1,205,263 | 0 | 0 | 0 | 491,322 | 0 | 0 | 0 | 0 | 0 |
Cash | 0 | 0 | 0 | 1,747 | 7,212 | 24,070 | 1,276,472 | 8,749,922 | 2,402,760 | 145,916 | 0 | 1,141,749 | 781,016 | 425,522 |
misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total current assets | 22,419,000 | 22,552,000 | 20,587,000 | 21,109,137 | 19,506,180 | 9,811,733 | 5,460,771 | 17,459,082 | 5,341,373 | 970,445 | 1,677,355 | 2,036,199 | 1,421,901 | 953,328 |
total assets | 25,909,000 | 26,109,000 | 24,214,000 | 22,980,823 | 20,576,881 | 10,607,300 | 5,727,834 | 17,775,442 | 6,009,427 | 2,317,871 | 3,204,269 | 3,814,656 | 2,971,901 | 2,537,032 |
Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Trade Creditors | 10,000 | 0 | 138,000 | 119,183 | 22,763 | 141,054 | 61,949 | 5,052 | 99,536 | 1,428,943 | 1,957,476 | 1,943,346 | 1,355,359 | 893,604 |
Group/Directors Accounts | 0 | 0 | 0 | 3,453,257 | 3,097,126 | 2,622,345 | 2,098,184 | 5,694,577 | 234,538 | 0 | 0 | 0 | 0 | 0 |
other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other current liabilities | 395,000 | 631,000 | 892,000 | 1,385,640 | 7,201,001 | 4,168,193 | 1,449,335 | 2,093,850 | 938,654 | 0 | 0 | 0 | 0 | 0 |
total current liabilities | 405,000 | 631,000 | 1,030,000 | 4,958,080 | 10,320,890 | 6,931,592 | 3,609,468 | 7,793,479 | 1,272,728 | 1,428,943 | 1,957,476 | 1,943,346 | 1,355,359 | 893,604 |
loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 328,724 | 1,082,087 | 1,236,715 | 935,000 | 1,079,305 |
provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 328,724 | 1,082,087 | 1,236,715 | 935,000 | 1,079,305 |
total liabilities | 405,000 | 631,000 | 1,030,000 | 4,958,080 | 10,320,890 | 6,931,592 | 3,609,468 | 7,793,479 | 1,272,728 | 1,757,667 | 3,039,563 | 3,180,061 | 2,290,359 | 1,972,909 |
net assets | 25,504,000 | 25,478,000 | 23,184,000 | 18,022,743 | 10,255,991 | 3,675,708 | 2,118,366 | 9,981,963 | 4,736,699 | 560,204 | 164,706 | 634,595 | 681,542 | 564,123 |
total shareholders funds | 25,460,000 | 25,478,000 | 23,184,000 | 18,022,743 | 10,255,991 | 3,675,708 | 2,118,366 | 9,981,963 | 4,736,699 | 560,204 | 164,706 | 634,595 | 681,542 | 564,123 |
Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Jan 2011 | Jan 2010 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Activities | ||||||||||||||
Operating Profit | -447,000 | 2,378,000 | 5,328,000 | 7,719,458 | 8,073,818 | 8,598,322 | 9,326,788 | 7,934,485 | 4,532,490 | 394,411 | ||||
Depreciation | 41,000 | 209,000 | 2,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Amortisation | 100,000 | 100,000 | 1,768,000 | 17,000 | 0 | 0 | 316,360 | 351,694 | 358,630 | 221,430 | 251,543 | 251,543 | 0 | 0 |
Tax | -22,000 | -84,000 | -204,000 | -1,150 | -1,523,167 | -1,539,554 | -1,829,473 | -1,708,027 | -384,450 | 0 | ||||
Stock | -128,000 | -680,000 | 376,972 | 49,543 | 65,969 | -102,016 | -120,173 | -124,724 | 344,476 | -393,451 | 311,361 | 111,773 | 38,334 | 249,936 |
Debtors | -5,000 | 2,645,000 | -897,362 | 1,558,879 | 9,645,336 | 5,705,380 | -4,404,688 | 5,895,271 | 1,769,608 | -459,375 | 471,544 | 141,792 | 41,041 | 311,574 |
Creditors | 10,000 | -138,000 | 18,817 | 96,420 | -118,291 | 79,105 | 56,897 | -94,484 | -1,329,407 | -528,533 | 14,130 | 587,987 | 461,755 | 893,604 |
Accruals and Deferred Income | -236,000 | -261,000 | -493,640 | -5,815,361 | 3,032,808 | 2,718,858 | -644,515 | 1,155,196 | 938,654 | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash flow from operations | -421,000 | 239,000 | 6,939,567 | 407,945 | -246,137 | 4,253,367 | 11,750,918 | 1,868,317 | 2,001,833 | 940,134 | ||||
Investing Activities | ||||||||||||||
capital expenditure | ||||||||||||||
Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -480,000 | 0 | 0 | 480,000 | 0 | 0 |
cash flow from investments | ||||||||||||||
Financing Activities | ||||||||||||||
Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Group/Directors Accounts | 0 | 0 | -3,453,257 | 356,131 | 474,781 | 524,161 | -3,596,393 | 5,460,039 | 234,538 | 0 | 0 | 0 | 0 | 0 |
Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -328,724 | -753,363 | -154,628 | 301,715 | -144,305 | 1,079,305 |
share issue | ||||||||||||||
interest | 451,000 | 0 | 37,000 | 56 | 769 | -137 | 10,196 | 24,518 | 28,455 | 0 | ||||
cash flow from financing | 451,000 | 0 | -3,416,000 | 356,187 | 475,548 | 524,024 | -3,586,197 | 5,484,557 | -65,731 | -752,923 | ||||
cash and cash equivalents | ||||||||||||||
cash | 0 | 0 | -1,747 | -5,465 | -16,858 | -1,252,402 | -7,473,450 | 6,347,162 | 2,256,844 | 145,916 | -1,141,749 | 360,733 | 355,494 | 425,522 |
overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
change in cash | 0 | 0 | -1,747 | -5,465 | -16,858 | -1,252,402 | -7,473,450 | 6,347,162 | 2,256,844 | 145,916 | -1,141,749 | 360,733 | 355,494 | 425,522 |
marlborough pharmaceuticals limited Credit Report and Business Information
Marlborough Pharmaceuticals Limited Competitor Analysis
Perform a competitor analysis for marlborough pharmaceuticals limited by selecting its closest rivals, whether from the ADMINISTRATIVE AND SUPPORT SERVICE ACTIVITIES sector, other micro companies, companies in SS14 area or any other competitors across 12 key performance metrics.
marlborough pharmaceuticals limited Ownership
MARLBOROUGH PHARMACEUTICALS LIMITED group structure
Marlborough Pharmaceuticals Limited has 1 subsidiary company.
Ultimate parent company
TRITON MANAGERS V LTD
#0131704
2 parents
MARLBOROUGH PHARMACEUTICALS LIMITED
05339752
1 subsidiary
marlborough pharmaceuticals limited directors
Marlborough Pharmaceuticals Limited currently has 6 directors. The longest serving directors include Mr Amit Patel (Aug 2019) and Mrs Neeshe Williams (Aug 2019).
officer | country | age | start | end | role |
---|---|---|---|---|---|
Mr Amit Patel | United Kingdom | 46 years | Aug 2019 | - | Director |
Mrs Neeshe Williams | United Kingdom | 43 years | Aug 2019 | - | Director |
Amit Patel | United Kingdom | 46 years | Aug 2019 | - | Director |
Felipe Florez | Switzerland | 48 years | Jun 2021 | - | Director |
Mr James Burt | United Kingdom | 50 years | Dec 2021 | - | Director |
Mr Santsagar Patel | United Kingdom | 51 years | Jun 2024 | - | Director |
P&L
March 2023turnover
4k
-100%
operating profit
-447k
-119%
gross margin
1275%
+1481.25%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2023net assets
25.5m
0%
total assets
25.9m
-0.01%
cash
0
0%
net assets
Total assets minus all liabilities
marlborough pharmaceuticals limited company details
company number
05339752
Type
Private limited with Share Capital
industry
82990 - Other business support service activities n.e.c.
incorporation date
January 2005
age
20
incorporated
UK
ultimate parent company
accounts
Total Exemption Full
last accounts submitted
March 2023
previous names
marlborough phamaceuticals limited (February 2005)
accountant
-
auditor
-
address
sovereign house miles gray road, basildon, essex, SS14 3FR
Bank
-
Legal Advisor
-
marlborough pharmaceuticals limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 7 charges/mortgages relating to marlborough pharmaceuticals limited. Currently there are 5 open charges and 2 have been satisfied in the past.
marlborough pharmaceuticals limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for MARLBOROUGH PHARMACEUTICALS LIMITED. This can take several minutes, an email will notify you when this has completed.
marlborough pharmaceuticals limited Companies House Filings - See Documents
date | description | view/download |
---|